03 SEP 2010 05:51 GI ACCRUAL REPORT - OPEN and recently closed STUDIES
REGS. REGS. REGS. REGS. REGS.
R LAST LAST LAST LAST LAST # of # of
E ACCR. TOTAL 12 6 3 30 7 ACT. CURR
STUDY G ARM GOAL REGS. Month Month Month DAYS DAYS INSTs IRBs
-------------------------------------- - --------------------------------- ----- ----- ----- ----- ----- ----- ----- ----- -----
S0518-Carcinoid,Adv,Octreo/Alpha/Bev 1 1 Octreotide, Bevacizumab 283 122 44 19 7 3 2 150 64
2 Octreotide,Interferon Alpha-2b 125 47 24 7 3 1
----- ----- ----- ----- ----- -----
247 91 43 14 6 3
* ***** ----- ***** *****
s 247
2 3 Octreotide, Bevacizumab 283 51 10 7 4 2 1 150 64
4 Octreotide,Interferon Alpha-2b 29 11 7 3 0 0
----- ----- ----- ----- ----- -----
80 21 14 7 2 1
* ***** ----- ***** *****
s 80
S0600-COLREC,MET,CHEMO+CETUX OR BEV 1 1 Cetuximab 671 16 0 0 0 0 0 234 101
2 Cetuximab + Lower Bevacizumab 18 0 0 0 0 0
3 Cetuximab + Higher Bevacizumab 17 0 0 0 0 0
4 TRNO A: Chemo + Cetuximab 9 9 6 3 0 0
5 TRNO B: Chemo + Bevacizumab 9 9 6 3 1 0
----- ----- ----- ----- ----- -----
69 18 12 6 1 0
* ***** ----- ***** *****
s 69
S0713-Rect,Stg2-3,Ox/Cape/Cet+RT->SRG 1 1 Oxal/Cape/Cetux + RT->Surgery 88 13 11 8 3 0 0 92 29
----- ----- ----- ----- ----- -----
13 11 8 3 0 0
* ***** ----- ***** *****
s 13
S0727-Panc,Met,Gem/Erlotinib/IMC-A12 1 1 Erlotinib+GEM+6 mg/kg IMC-A12 118 10 0 0 0 0 0 165 73
4 Erlotinib + GEM + IMC-A12 60 55 31 16 8 3
5 Erlotinib + Gemcitabine 64 61 33 16 7 2
----- ----- ----- ----- ----- -----
134 116 64 32 15 5
* ***** ----- ***** *****
s 134
S0809-EHCC,Adj,Cape+Gem==>Cape+RT 1 1 Cape+Gem=>Cape+RT 88 32 26 22 10 4 1 163 70
----- ----- ----- ----- ----- -----
32 26 22 10 4 1
* ***** ----- ***** *****
s 32
S0941-GallChol,Adv,Sorafenib/Erlotinib 1 1 Sorafenib, Erlotinib 55 3 3 3 3 1 0 111 39
----- ----- ----- ----- ----- -----
3 3 3 3 1 0
* ***** ----- ***** *****
s 3
C80405-GI,Met,FOLFOX/FIRI,Bev,Cetux 1 Total Registrations 2289 527 62 33 16 3 0 337 181
----- ----- ----- ----- ----- -----
527 62 33 16 3 0
* ***** ----- ***** *****
s 527
E5202-Colon,Stg2,5FU/Leuc/Oxal +/- Bev 1 Total Registrations 356 68 39 18 6 0 159
----- ----- ----- ----- ----- -----
356 68 39 18 6 0
* ***** ----- ***** *****
s 356
R04-Rectum, Capecitabine vs 5FU 1 Total Registrations 49 11 4 1 0 0 263 125
----- ----- ----- ----- ----- -----
49 11 4 1 0 0
* ***** ----- ***** *****
s 49
18 rows selected.
03 SEP 2010 05:51 GI Open Studies with No Registrations
Study Registration/Phase Open Date
---------------------------------------- ----------------------------------- ---------
C80702 Adj FOLFOX+Celecoxib or Placebo 1 Endorsed Study 22-Jun-10
E1208 Chemo Soraf. in Unresect HCC 1 Endorsed Study 09-Nov-09
R0848 Panc, Adj, Erlotinib v ChemoRT 1 Endorsed Study 08-Dec-09
3 rows selected.
03 SEP 2010 05:51 GI Recently Closed Studies Accrual Report
O
P REGS. REGS.
E DATE TOTAL LAST LAST
N CLOSED REG. ARM REGS. 30 DAYS 7 DAYS
- ---------- ---- --------------------------------- ------ ------- ------
N 01-Sep-10 1 1 Erlotinib+GEM+6 mg/kg IMC-A12 10 0 0
4 Erlotinib + GEM + IMC-A12 60 8 3
5 Erlotinib + Gemcitabine 64 7 2
------ ------- ------
134 15 5
3 rows selected.
03 SEP 2010 05:51 page 1
GI SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES
R
E TOTAL
STUDY G ARM SEGMENT REGS.
-------------------------------------- - --------------------------------- ----------------------------------- -----
S0600-COLREC,MET,CHEMO+CETUX OR BEV 1 1 Cetuximab 01: Cycle 16
1 Cetuximab 02: Cycle 14
1 Cetuximab 03: Cycle 11
1 Cetuximab 04: Cycle 10
1 Cetuximab 05: Cycle 9
1 Cetuximab 06: Cycle 7
1 Cetuximab 07: Cycle 4
1 Cetuximab 08: Cycle 3
1 Cetuximab 09: Cycle 2
1 Cetuximab 10: Cycle 2
1 Cetuximab 11: Cycle 2
1 Cetuximab 12: Cycle 2
1 Cetuximab 13: Cycle 2
1 Cetuximab 14: Cycle 2
1 Cetuximab 15: Cycle 2
1 Cetuximab 16: Cycle 2
1 Cetuximab 17: Cycle 2
1 Cetuximab 18: Cycle 1
2 Cetuximab + Lower Bevacizumab 01: Cycle 18
2 Cetuximab + Lower Bevacizumab 02: Cycle 17
2 Cetuximab + Lower Bevacizumab 03: Cycle 13
2 Cetuximab + Lower Bevacizumab 04: Cycle 13
2 Cetuximab + Lower Bevacizumab 05: Cycle 12
2 Cetuximab + Lower Bevacizumab 06: Cycle 9
2 Cetuximab + Lower Bevacizumab 07: Cycle 7
2 Cetuximab + Lower Bevacizumab 08: Cycle 5
2 Cetuximab + Lower Bevacizumab 09: Cycle 5
2 Cetuximab + Lower Bevacizumab 10: Cycle 3
2 Cetuximab + Lower Bevacizumab 11: Cycle 4
2 Cetuximab + Lower Bevacizumab 12: Cycle 4
2 Cetuximab + Lower Bevacizumab 13: Cycle 3
2 Cetuximab + Lower Bevacizumab 14: Cycle 3
2 Cetuximab + Lower Bevacizumab 15: Cycle 3
2 Cetuximab + Lower Bevacizumab 16: Cycle 3
2 Cetuximab + Lower Bevacizumab 17: Cycle 3
2 Cetuximab + Lower Bevacizumab 18: Cycle 3
2 Cetuximab + Lower Bevacizumab 19: Cycle 3
03 SEP 2010 05:51 page 2
GI SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES
R
E TOTAL
STUDY G ARM SEGMENT REGS.
-------------------------------------- - --------------------------------- ----------------------------------- -----
S0600-COLREC,MET,CHEMO+CETUX OR BEV 1 2 Cetuximab + Lower Bevacizumab 20: Cycle 3
2 Cetuximab + Lower Bevacizumab 21: Cycle 2
2 Cetuximab + Lower Bevacizumab 22: Cycle 2
2 Cetuximab + Lower Bevacizumab 23: Cycle 1
2 Cetuximab + Lower Bevacizumab 24: Cycle 1
2 Cetuximab + Lower Bevacizumab 25: Cycle 1
2 Cetuximab + Lower Bevacizumab 26: Cycle 1
2 Cetuximab + Lower Bevacizumab 27: Cycle 1
2 Cetuximab + Lower Bevacizumab 28: Cycle 1
2 Cetuximab + Lower Bevacizumab 29: Cycle 1
2 Cetuximab + Lower Bevacizumab 30: Cycle 1
2 Cetuximab + Lower Bevacizumab 31: Cycle 1
2 Cetuximab + Lower Bevacizumab 32: Cycle 1
3 Cetuximab + Higher Bevacizumab 01: Cycle 17
3 Cetuximab + Higher Bevacizumab 02: Cycle 16
3 Cetuximab + Higher Bevacizumab 03: Cycle 16
3 Cetuximab + Higher Bevacizumab 04: Cycle 12
3 Cetuximab + Higher Bevacizumab 05: Cycle 11
3 Cetuximab + Higher Bevacizumab 06: Cycle 9
3 Cetuximab + Higher Bevacizumab 07: Cycle 8
3 Cetuximab + Higher Bevacizumab 08: Cycle 7
3 Cetuximab + Higher Bevacizumab 09: Cycle 6
3 Cetuximab + Higher Bevacizumab 10: Cycle 5
3 Cetuximab + Higher Bevacizumab 11: Cycle 5
3 Cetuximab + Higher Bevacizumab 12: Cycle 5
3 Cetuximab + Higher Bevacizumab 13: Cycle 4
3 Cetuximab + Higher Bevacizumab 14: Cycle 3
3 Cetuximab + Higher Bevacizumab 15: Cycle 3
3 Cetuximab + Higher Bevacizumab 16: Cycle 3
3 Cetuximab + Higher Bevacizumab 17: Cycle 3
3 Cetuximab + Higher Bevacizumab 18: Cycle 3
3 Cetuximab + Higher Bevacizumab 19: Cycle 2
3 Cetuximab + Higher Bevacizumab 20: Cycle 2
3 Cetuximab + Higher Bevacizumab 21: Cycle 2
3 Cetuximab + Higher Bevacizumab 22: Cycle 1
3 Cetuximab + Higher Bevacizumab 23: Cycle 1
3 Cetuximab + Higher Bevacizumab 24: Cycle 1
03 SEP 2010 05:51 page 3
GI SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES
R
E TOTAL
STUDY G ARM SEGMENT REGS.
-------------------------------------- - --------------------------------- ----------------------------------- -----
S0600-COLREC,MET,CHEMO+CETUX OR BEV 1 3 Cetuximab + Higher Bevacizumab 25: Cycle 1
3 Cetuximab + Higher Bevacizumab 26: Cycle 1
3 Cetuximab + Higher Bevacizumab 27: Cycle 1
3 Cetuximab + Higher Bevacizumab 28: Cycle 1
4 TRNO A: Chemo + Cetuximab 01: Cycle 9
4 TRNO A: Chemo + Cetuximab 02: Cycle 4
4 TRNO A: Chemo + Cetuximab 03: Cycle 3
4 TRNO A: Chemo + Cetuximab 04: Cycle 1
4 TRNO A: Chemo + Cetuximab 05: Cycle 1
4 TRNO A: Chemo + Cetuximab 06: Cycle 1
4 TRNO A: Chemo + Cetuximab 07: Cycle 1
4 TRNO A: Chemo + Cetuximab 08: Cycle 1
4 TRNO A: Chemo + Cetuximab 09: Cycle 1
4 TRNO A: Chemo + Cetuximab 10: Cycle 1
4 TRNO A: Chemo + Cetuximab 11: Cycle 1
4 TRNO A: Chemo + Cetuximab 12: Cycle 1
4 TRNO A: Chemo + Cetuximab 13: Cycle 1
5 TRNO B: Chemo + Bevacizumab 01: Cycle 9
5 TRNO B: Chemo + Bevacizumab 02: Cycle 5
5 TRNO B: Chemo + Bevacizumab 03: Cycle 5
5 TRNO B: Chemo + Bevacizumab 04: Cycle 4
5 TRNO B: Chemo + Bevacizumab 05: Cycle 3
5 TRNO B: Chemo + Bevacizumab 06: Cycle 1
5 TRNO B: Chemo + Bevacizumab 07: Cycle 1
5 TRNO B: Chemo + Bevacizumab 08: Cycle 1
5 TRNO B: Chemo + Bevacizumab 09: Cycle 1
5 TRNO B: Chemo + Bevacizumab 10: Cycle 1
5 TRNO B: Chemo + Bevacizumab 11: Cycle 1
5 TRNO B: Chemo + Bevacizumab 12: Cycle 1
5 TRNO B: Chemo + Bevacizumab 13: Cycle 1
5 TRNO B: Chemo + Bevacizumab 14: Cycle 1
S0713-Rect,Stg2-3,Ox/Cape/Cet+RT->SRG 1 1 Oxal/Cape/Cetux + RT->Surgery 01: Chemotherapy 13
1 Oxal/Cape/Cetux + RT->Surgery 02: Chemotherapy plus Radiation 3
03 SEP 2010 05:51 page 4
GI SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES
R
E TOTAL
STUDY G ARM SEGMENT REGS.
-------------------------------------- - --------------------------------- ----------------------------------- -----
S0727-Panc,Met,Gem/Erlotinib/IMC-A12 1 1 Erlotinib+GEM+6 mg/kg IMC-A12 01: 1 treatment cycle 10
1 Erlotinib+GEM+6 mg/kg IMC-A12 02: 1 treatment cycle 8
1 Erlotinib+GEM+6 mg/kg IMC-A12 03: 1 treatment cycle 2
1 Erlotinib+GEM+6 mg/kg IMC-A12 04: 1 treatment cycle 1
4 Erlotinib + GEM + IMC-A12 01: 1 treatment cycle 60
4 Erlotinib + GEM + IMC-A12 02: 1 treatment cycle 35
4 Erlotinib + GEM + IMC-A12 03: 1 treatment cycle 21
4 Erlotinib + GEM + IMC-A12 04: 1 treatment cycle 15
4 Erlotinib + GEM + IMC-A12 05: 1 treatment cycle 10
4 Erlotinib + GEM + IMC-A12 06: 1 treatment cycle 6
4 Erlotinib + GEM + IMC-A12 07: 1 treatment cycle 2
4 Erlotinib + GEM + IMC-A12 08: 1 treatment cycle 1
4 Erlotinib + GEM + IMC-A12 09: 1 treatment cycle 1
5 Erlotinib + Gemcitabine 01: 1 treatment cycle 64
5 Erlotinib + Gemcitabine 02: 1 treatment cycle 42
5 Erlotinib + Gemcitabine 03: 1 treatment cycle 23
5 Erlotinib + Gemcitabine 04: 1 treatment cycle 13
5 Erlotinib + Gemcitabine 05: 1 treatment cycle 8
5 Erlotinib + Gemcitabine 06: 1 treatment cycle 6
5 Erlotinib + Gemcitabine 07: 1 treatment cycle 4
5 Erlotinib + Gemcitabine 08: 1 treatment cycle 1
5 Erlotinib + Gemcitabine 09: 1 treatment cycle 1
5 Erlotinib + Gemcitabine 10: 1 treatment cycle 1
S0809-EHCC,Adj,Cape+Gem==>Cape+RT 1 1 Cape+Gem=>Cape+RT 01: Adj. Chemo Cycle 1 32
1 Cape+Gem=>Cape+RT 02: Adj. Chemo Cycle 2 21
1 Cape+Gem=>Cape+RT 03: Adj. Chemo Cycle 3 15
1 Cape+Gem=>Cape+RT 04: Adj. Chemo Cycle 4 11
1 Cape+Gem=>Cape+RT 05: Chemoradiotherapy 6
S0941-GallChol,Adv,Sorafenib/Erlotinib 1 1 Sorafenib, Erlotinib 01: CYCLE 3
136 rows selected.
SWOG StatCtr Home Page
1 row selected.